Background
SURPASS-1 was the foundational monotherapy trial of tirzepatide, the first approved dual GIP/GLP-1 receptor agonist (brand name Mounjaro). As the monotherapy arm of the SURPASS program, it was designed to evaluate tirzepatide’s intrinsic efficacy — independent of background antidiabetic therapy — in adults with type 2 diabetes who had not previously received pharmacological treatment beyond lifestyle modification.
The trial’s value lies in isolating the direct glycemic and weight effects of dual incretin co-agonism without the confounding effects of add-on therapy interactions, establishing the clean efficacy signal for tirzepatide as a standalone agent in treatment-naive T2D patients.
Methods
Design: Multicenter, randomized, double-blind, placebo-controlled trial
Population: 705 adults with T2D (HbA1c 7.0–9.5%) managed with diet and exercise alone (no prior antidiabetic pharmacotherapy); BMI ≥23 kg/m²
Treatment arms:
- Tirzepatide 5 mg/week (n=175)
- Tirzepatide 10 mg/week (n=175)
- Tirzepatide 15 mg/week (n=178)
- Placebo (n=177)
Duration: 40 weeks (dose escalation over first 20 weeks; maintenance 20 weeks)
Primary endpoint: Change in HbA1c from baseline at 40 weeks
Key Findings
Primary Outcome — HbA1c Reduction:
| Treatment | Baseline HbA1c | Change at 40 Weeks | vs. Placebo |
|---|---|---|---|
| Tirzepatide 5 mg | ~8.0% | −1.87% | −1.84% (p < 0.001) |
| Tirzepatide 10 mg | ~8.0% | −1.89% | −1.86% (p < 0.001) |
| Tirzepatide 15 mg | ~8.0% | −2.11% | −2.08% (p < 0.001) |
| Placebo | ~8.0% | −0.03% | — |
All three tirzepatide doses achieved highly statistically significant and clinically meaningful HbA1c reductions vs. placebo (all p < 0.001).
Proportion Achieving Glycemic Targets:
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|---|
| HbA1c < 7.0% | 82% | 80% | 87% | 20% |
| HbA1c ≤ 6.5% | 47% | 47% | 59% | 7% |
| HbA1c < 5.7% (normal) | 3% | 7% | 27% | 1% |
- 27% of the tirzepatide 15 mg group achieved HbA1c in the non-diabetic normal range (< 5.7%) — an unprecedented pharmacological outcome in T2D
- 87% achieving HbA1c < 7.0% on monotherapy exceeds outcomes typical of established single-agent antidiabetics (metformin ~50%, DPP-4 inhibitors ~30–40%, GLP-1 agonists ~60–70%)
Body Weight Reduction:
| Treatment | Weight Change | vs. Placebo |
|---|---|---|
| Tirzepatide 5 mg | −7.0 kg | −6.8 kg (p < 0.001) |
| Tirzepatide 10 mg | −7.8 kg | −7.6 kg (p < 0.001) |
| Tirzepatide 15 mg | −9.5 kg | −9.3 kg (p < 0.001) |
| Placebo | −0.2 kg | — |
- Weight loss of −9.5 kg in drug-naive T2D patients on a single agent is exceptional — historically, significant weight loss in T2D required combination therapy or bariatric surgery
- Weight reductions at 5 mg and 10 mg nearly as large as 15 mg, suggesting a relatively flat dose-response for weight in this population
Safety:
- GI adverse events: nausea 12–18% tirzepatide vs 6% placebo; diarrhea 9–14% vs 6%; vomiting 4–8% vs 2%
- GI events primarily during dose escalation phase; largely resolved by maintenance
- Hypoglycemia (< 54 mg/dL): < 1% across all tirzepatide groups — importantly low for monotherapy without sulfonylurea
- No pancreatitis, thyroid malignancy, or new-onset retinopathy signals
- Discontinuation due to AEs: 5.1% (15 mg) vs 0.6% (placebo)
Mechanism in Treatment-Naive Patients
In drug-naive T2D patients, the dual GIP/GLP-1 mechanism provides:
- GIP-mediated beta cell protection: GIP receptor activation in pancreatic beta cells promotes cell survival and insulin synthesis — preserving residual beta cell function present in newly diagnosed T2D
- Appetite suppression: Both receptor axes converge on hypothalamic satiety circuits, reducing food intake without the pharmacological side effects of older appetite-suppressing drugs
- Complementary insulin secretion: GIP and GLP-1 stimulate insulin via distinct pathways; their combination produces supraadditive insulin secretion in hyperglycemic conditions without hypoglycemia risk in euglycemia
Clinical Significance
- Monotherapy efficacy ceiling raised: SURPASS-1 demonstrates that tirzepatide monotherapy outperforms the combination efficacy of many two-drug T2D regimens — potentially enabling later intensification timelines
- Normoglycemia in T2D: Achieving HbA1c in the normal range for 27% of patients on monotherapy — a level of efficacy no prior T2D agent demonstrated at this scale
- Weight as therapeutic co-benefit: −9.5 kg weight loss in T2D patients is clinically relevant for cardiovascular risk reduction, sleep apnea, and joint disease beyond glycemic control
- Basis for obesity indication: The weight loss magnitude in T2D patients (−9.5 kg) directly foreshadowed tirzepatide’s anti-obesity outcomes in non-diabetic patients (SURMOUNT program, −20%+ body weight)
Limitations
- Drug-naive T2D population with relatively mild baseline HbA1c (mean ~8.0%); results in patients with longer T2D duration, higher baseline HbA1c, or multiple antidiabetic failures may differ
- 40-week duration; long-term durability of glycemic control and weight loss, and cardiovascular outcomes, require longer-term trials
- Predominantly White (59%) male (54%) population — generalizability to diverse populations requires additional study
- Open-label titration not applicable here (placebo-controlled, double-blind) — but blinding in the SURPASS program used different volume matching which could introduce some unblinding risk
- No comparison to active comparator — SURPASS-2 provides the semaglutide head-to-head data; SURPASS-1 isolates placebo-controlled monotherapy effects